Physician profile
Roy C Bliley
NPI 1225092992
$3,052.73
in general payments reported to CMS, 2019-2025
24 companies · $82.59 in 2025
The $82.59 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $392 · 2021: $461 · 2022: $357 · 2023: $618 · 2024: $763 · 2025: $82.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $957.79 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $357.82 | 2019-2022 | |
| Pfizer INC. | $344.69 | 2019-2024 | |
| Medtronic, INC. | $199.89 | 2021-2024 | Onyx Frontier, Symplicity G3 |
| Medtronic Vascular, INC. | $143.77 | 2020 | |
| Amgen INC. | $135.05 | 2019-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $119.30 | 2021 | |
| Novo Nordisk INC | $106.24 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $100.70 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $92.23 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $89.97 | 2019-2023 | |
| Scpharmaceuticals INC. | $58.64 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.49 | 2021-2024 | Jardiance |
| Abbott Laboratories | $46.07 | 2022-2023 | Cardiomems |
| Inspire Medical Systems, INC. | $42.38 | 2023-2024 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $35.80 | 2020 | |
| Sanofi-Aventis U.S. LLC | $35.61 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $30.06 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.36 | 2022-2025 | Camzyos |
| Edwards Lifesciences Corporation | $19.24 | 2024 | |
| Cmp Pharma, INC. | $18.31 | 2020 | |
| Merck Sharp & Dohme LLC | $16.23 | 2022 | |
| Chiesi USA, INC. | $14.38 | 2022 | |
| Infobionic, INC | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Bliley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.